BACKGROUND: The clinical significance of the plasmacytoid variant (PCV) in urothelial carcinoma (UC) is currently lacking. OBJECTIVE: To compare clinical outcomes of patients with any PCV with that of patients with pure UC treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We identified 98 patients who had pathologically confirmed PCV UC and 1312 patients with pure UC and no variant history who underwent RC at our institution between 1995 and 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox regression and Cox proportional hazards regression to determine if PCV was associated with overall survival (OS). RESULTS AND LIMITATIONS: Patients with PCV UC were more likely to have advanced tumor stage (p=0.001), positive lymph nodes (p=0.038), and receive neoadjuvant chemotherapy than those with pure UC (46% vs 22%, p<0.0001). The rate of positive soft tissue surgical margins was over five times greater in the PCV UC group compared with the pure UC group (21% vs 4.1%, respectively, p<0.0001). Median OS for the pure UC versus the PCV patients were 8 yr and 3.8 yr, respectively. On univariable analysis, PCV was associated with an increased risk of overall mortality (hazard ratio=1.34, 95% confidence interval: 1.02-1.78, p=0.039). However, on multivariable analysis adjusted for age, sex, neoadjuvant chemotherapy received, lymph node status, pathologic stage, and soft margin status, the association between PCV and OS was no longer significant (hazard ratio=1.06, 95% confidence interval: 0.78, 1.43, p=0.7). This retrospective study is limited by the lack of pathological reanalysis, and the impact of other concurrent mixed histology cannot be determined in this study. CONCLUSIONS: Patients with PCV features have a higher disease burden at RC compared with those with pure UC. However, PCV was not an independent predictor of survival after RC on multivariable analysis, suggesting that PCV histology should not be used as an independent prognostic factor. PATIENT SUMMARY: Plasmacytoid urothelial carcinoma is a rare and aggressive form of bladder cancer. Patients with plasmacytoid urothelial carcinoma had worse adverse pathologic features, but this was not associated with worse overall mortality when compared with patients with pure urothelial carcinoma.
BACKGROUND: The clinical significance of the plasmacytoid variant (PCV) in urothelial carcinoma (UC) is currently lacking. OBJECTIVE: To compare clinical outcomes of patients with any PCV with that of patients with pure UC treated with radical cystectomy (RC). DESIGN, SETTING, AND PARTICIPANTS: We identified 98 patients who had pathologically confirmed PCVUC and 1312 patients with pure UC and no variant history who underwent RC at our institution between 1995 and 2014. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Univariable and multivariable Cox regression and Cox proportional hazards regression to determine if PCV was associated with overall survival (OS). RESULTS AND LIMITATIONS: Patients with PCVUC were more likely to have advanced tumor stage (p=0.001), positive lymph nodes (p=0.038), and receive neoadjuvant chemotherapy than those with pure UC (46% vs 22%, p<0.0001). The rate of positive soft tissue surgical margins was over five times greater in the PCVUC group compared with the pure UC group (21% vs 4.1%, respectively, p<0.0001). Median OS for the pure UC versus the PCVpatients were 8 yr and 3.8 yr, respectively. On univariable analysis, PCV was associated with an increased risk of overall mortality (hazard ratio=1.34, 95% confidence interval: 1.02-1.78, p=0.039). However, on multivariable analysis adjusted for age, sex, neoadjuvant chemotherapy received, lymph node status, pathologic stage, and soft margin status, the association between PCV and OS was no longer significant (hazard ratio=1.06, 95% confidence interval: 0.78, 1.43, p=0.7). This retrospective study is limited by the lack of pathological reanalysis, and the impact of other concurrent mixed histology cannot be determined in this study. CONCLUSIONS:Patients with PCV features have a higher disease burden at RC compared with those with pure UC. However, PCV was not an independent predictor of survival after RC on multivariable analysis, suggesting that PCV histology should not be used as an independent prognostic factor. PATIENT SUMMARY: Plasmacytoid urothelial carcinoma is a rare and aggressive form of bladder cancer. Patients with plasmacytoid urothelial carcinoma had worse adverse pathologic features, but this was not associated with worse overall mortality when compared with patients with pure urothelial carcinoma.
Authors: Bastian Keck; Robert Stoehr; Sven Wach; Anja Rogler; Ferdinand Hofstaedter; Jan Lehmann; Rodolfo Montironi; Mathilde Sibonye; Hans M Fritsche; Antonio Lopez-Beltran; Jonathan I Epstein; Bernd Wullich; Arndt Hartmann Journal: Int J Cancer Date: 2010-12-01 Impact factor: 7.396
Authors: Roberto Rafael Ricardo-Gonzalez; Michael Nguyen; Neriman Gokden; Ankur R Sangoi; Joseph C Presti; Jesse K McKenney Journal: J Urol Date: 2012-01-15 Impact factor: 7.450
Authors: Ganesh V Raj; Raanan Tal; Andrew Vickers; Bernard H Bochner; Angel Serio; S Machele Donat; Harry Herr; Semra Olgac; Guido Dalbagni Journal: Cancer Date: 2006-11-01 Impact factor: 6.860
Authors: Leonidas N Diamantopoulos; Ali Raza Khaki; Petros Grivas; John L Gore; George R Schade; Andrew C Hsieh; John K Lee; Todd Yezefski; Evan Y Yu; Michael T Schweizer; Heather H Cheng; Sarah P Psutka; Daniel W Lin; Maria S Tretiakova; Funda Vakar-Lopez; Robert B Montgomery; Jonathan L Wright Journal: Bladder Cancer Date: 2020-03-28
Authors: Gabriele Sorce; Rocco Simone Flammia; Benedikt Hoeh; Francesco Chierigo; Benedikt Horlemann; Christoph Würnschimmel; Zhe Tian; Markus Graefen; Carlo Terrone; Michele Gallucci; Felix K H Chun; Fred Saad; Shahrokh F Shariat; Francesco Montorsi; Alberto Briganti; Pierre I Karakiewicz Journal: World J Urol Date: 2022-01-27 Impact factor: 3.661